Similar articles

• Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control.

  Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Argüelles A, Llorente L. Diaz-Borjon A, et al. Joint Bone Spine. 2000 Jan;67(1):40-8. Joint Bone Spine. 2000. PMID: 10773967
• P-glycoprotein in autoimmune diseases.

  Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. Richaud-Patin Y, et al. Autoimmun Rev. 2004 Mar;3(3):188-92. doi: 10.1016/j.autrev.2003.08.002. Autoimmun Rev. 2004. PMID: 15110230 Review.
• [MDR (Multiple Drug Resistant) type of resistance to chemotherapy in clinical practice].

  Oudard S, Marie JP, Pujade Lauraine E. Oudard S, et al. Bull Cancer. 1996 Aug;83(8):609-18. Bull Cancer. 1996. PMID: 8869040 Review. French.
• Iodination increases the activity of verapamil derivatives in reversing PGP multidrug resistance.

  Barattin R, Gerby B, Bourges K, Hardy G, Olivares J, Boutonnat J, Arnoult C, D'Hardemare AD, Ronot X. Barattin R, et al. Anticancer Res. 2010 Jul;30(7):2553-9. Anticancer Res. 2010. PMID: 20682982
• Cell membrane perturbations and vincristine transport in sensitive and resistant HL-60 cell lines.

  Zichner S, Zimmer G, Woodcock BG. Zichner S, et al. Int J Clin Pharmacol Ther. 1998 Feb;36(2):99-102. Int J Clin Pharmacol Ther. 1998. PMID: 9520157 No abstract available.